Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

Ioanna Stamati; Gökhan Yahioglu; Soraya Diez-Posada; Anja Pomowski; Isabel Perez-Castro; A. Keith Stewart; Laura Bouché; Antony Constantinou; Benjamin J. Stenton; Savvas Saouros; Bryan Edwards; Sam Ness; Mahendra P. Deonarain

doi:10.1158/1535-7163.30029711

September 2, 2025Open Access

Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

View Full Paper

Ask AI

Bookmark

Share

Key Points

Anti-HER2 drug conjugates exhibit superior efficacy than IgG-based ADCs, potentially transforming treatment options.
The study highlights a glucuronide-based MMAE linker as key to increased therapeutic impact in targeted therapies.
A detailed 3D structural model of scFv reveals lysine arrangements, crucial for understanding binding efficacy.
Future implications may lead to improved antibody fragment designs in the development of targeted drug therapies.

Implication

Findings demonstrate superior efficacy of anti-HER2 drug conjugates with a glucuronide-based MMAE linker, suggesting advancements in antibody-based therapies.

Abstract

Supplementary Figure 3 showing the 3D structural model of the TCT(H) scFv highlighting lysine arrangement and full amino acid sequence

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stamati et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02b0f https://doi.org/10.1158/1535-7163.30029711

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 3 from Anti-HER2, High-DAR Antibody Fragment–Drug Conjugates with a Glucuronide-Based MMAE Linker–Payload Demonstrate Superior Efficacy over IgG-Based ADCs

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading